Aktis Oncology, Inc. 10-K — AI Bull & Bear Analysis

The 10-K filing reveals a high-stakes binary bet on the viability of miniprotein radioconjugates. The synthesis of the data suggests that while Aktis has successfully solved several technical hurdles regarding tumor uptake and renal clearance, it has yet to solve the fundamental business risks of isotope procurement and intellectual property exclusivity. The partnership with Eli Lilly serves as a powerful external validation of the platform's potential, but it does not eliminate the clinical risks associated with Phase 1b trials. Ultimately, the investment thesis hinges on the Q1 2027 dose-escalation data and the successful launch of the internal cGMP facility. If Aktis can prove clinical efficacy while simultaneously securing its supply chain and manufacturing, it could capture a significant portion of the projected $26 billion radiopharmaceutical market. However, the lack of payload patents and the geopolitical risk of isotope sourcing remain the primary headwinds that could derail this trajectory.